Abstract
24 - A phase II study of rapid cycling high dose testosterone (Bipolar Androgen Therapy) in men with metastatic castrate-resistant prostate cancer (mCRPC) resistant to abiraterone and/or enzalutamide
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have